453 related articles for article (PubMed ID: 16444866)
21. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
22. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
23. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
24. Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells.
Novella S; Laguna-Fernández A; Lázaro-Franco M; Sobrino A; Bueno-Betí C; Tarín JJ; Monsalve E; Sanchís J; Hermenegildo C
Mol Cell Endocrinol; 2013 Jan; 365(1):11-6. PubMed ID: 22982060
[TBL] [Abstract][Full Text] [Related]
25. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
Tan B; Jiang DJ; Huang H; Jia SJ; Jiang JL; Hu CP; Li YJ
Vascul Pharmacol; 2007 May; 46(5):338-45. PubMed ID: 17293168
[TBL] [Abstract][Full Text] [Related]
26. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
27. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons.
Selley ML
J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741
[TBL] [Abstract][Full Text] [Related]
28. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
29. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.
Achan V; Tran CT; Arrigoni F; Whitley GS; Leiper JM; Vallance P
Circ Res; 2002 Apr; 90(7):764-9. PubMed ID: 11964368
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T
Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680
[TBL] [Abstract][Full Text] [Related]
31. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
32. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
33. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.
Pope AJ; Karuppiah K; Cardounel AJ
Pharmacol Res; 2009 Dec; 60(6):461-5. PubMed ID: 19682581
[TBL] [Abstract][Full Text] [Related]
34. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
Stühlinger MC; Conci E; Haubner BJ; Stocker EM; Schwaighofer J; Cooke JP; Tsao PS; Pachinger O; Metzler B
Cardiovasc Res; 2007 Jul; 75(2):417-25. PubMed ID: 17559823
[TBL] [Abstract][Full Text] [Related]
35. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
Ghebremariam YT; LePendu P; Lee JC; Erlanson DA; Slaviero A; Shah NH; Leiper J; Cooke JP
Circulation; 2013 Aug; 128(8):845-53. PubMed ID: 23825361
[TBL] [Abstract][Full Text] [Related]
36. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects.
Holven KB; Haugstad TS; Holm T; Aukrust P; Ose L; Nenseter MS
Br J Nutr; 2003 Mar; 89(3):359-63. PubMed ID: 12628031
[TBL] [Abstract][Full Text] [Related]
37. Dimethylarginine dimethylaminohydrolase: a new therapeutic target for the modulation of nitric oxide and angiogenesis.
Singh JP
Curr Opin Investig Drugs; 2007 Sep; 8(9):736-41. PubMed ID: 17729185
[TBL] [Abstract][Full Text] [Related]
38. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
39. Basal release of nitric oxide in the mesenteric artery in portal hypertension and cirrhosis: role of dimethylarginine dimethylaminohydrolase.
Serna E; Mauricio MD; Lluch P; Segarra G; Cortina B; Lluch S; Medina P
J Gastroenterol Hepatol; 2013 May; 28(5):880-6. PubMed ID: 23302093
[TBL] [Abstract][Full Text] [Related]
40. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia.
Doshi S; McDowell I; Goodfellow J; Stabler S; Boger R; Allen R; Newcombe R; Lewis M; Moat S
Metabolism; 2005 Mar; 54(3):351-60. PubMed ID: 15736113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
